May 18, 2022
Iwate Tohoku Medical Megabank Organization, Iwate Medical University
Keio University School of Medicine
National Cancer Center
A research group, including Project Associate Professor Hideki Omomo and Professor Atsushi Shimizu (Head of the Division) from the Division of Biomedical Information Analysis at the Iwate Tohoku Medical Megabank Organization (IMM), Iwate Medical University; Professor Yae Kanai and Associate Professor Eri Arai from the Department of Pathology, Keio University School of Medicine; and Deputy Director Hiroyuki Fujimoto and Department Head Teruhiko Yoshida (Department of Genetic Medicine and Services) from the National Cancer Center Hospital, conducted a DNA methylation analysis on whole blood-derived DNA from 50 patients with clear cell renal cell carcinoma (ccRCC), a major type of renal cell carcinoma, and 50 controls. In their search for CpG sites with altered DNA methylation status associated with ccRCC, they discovered that six CpG sites located on the PCBD2/MTND4P12 gene on chromosome 5 could serve as novel DNA methylation biomarkers for ccRCC.
Furthermore, the utility of these biomarkers was validated in a separate, independent cohort of 48 ccRCC patients and 48 controls, demonstrating their significant utility as DNA methylation markers for ccRCC. The findings of this study were published online in the international scientific journal Epigenetics Communications on May 2, 2022.
Please see below for the full press release.